AstraZeneca autosomal dominant polycystic kidney disease drug gets orphan status
AstraZeneca Pharmaceuticals' treatment of autosomal dominant polycystic kidney disease was granted FDA orphan designation, according to a post to the agency's website. Reference Link
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.